Led by Tiger Global and Insight Partners, the funding round valued the AI-powered disease detection and care coordination platform at $1.2bn
The number of hospitals using the Viz Platform has crossed the 1,000 mark. (Credit: geralt from Pixabay)
Viz.ai has secured a $100m funding in the Series D round that valued the AI-driven healthcare platform provider at $1.2bn.
The funding round was led by Tiger Global and Insight Partners and also saw participation from early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV, Sozo Ventures, CRV, and Susa.
Viz.ai will use the funds to accelerate its growth, expand the product portfolio in the detection and triage of more diseases and grow its customer base around the world.
According to the company, the number of hospitals using the Viz Platform has crossed the 1,000 mark.
The Viz Platform is an intelligent care coordination solution that integrates synchronised care collaboration, high fidelity mobile image viewing, automated workflows and enhanced visibility at decision-making moments.
Viz.ai co-founder and CEO Chris Mansi said: “Viz.ai is committed to helping patients get better, faster and more equitable access to life saving treatments.
“We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system.
“More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
The company has rolled out AI-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms over the past year.
Viz.ai has also launched an innovative AI-driven life science platform, a first-of-its-kind solution to ease the way medical device and pharmaceutical firms conduct clinical trials.
It has facilities in San Francisco, Tel Aviv, Portugal and Amsterdam and has expanded its employee count to more than 350 from 180 over the past 12 months.
Mount Sinai Health System cerebrovascular neurosurgeon Chris Kellner said: “The Viz.ai platform has been the single most impactful advance I’ve seen as a physician, permitting the entire care team to mobilize immediately and deliver time sensitive treatment faster.
“In addition, Viz Recruit permits us to automatically screen patients for clinical trial enrollment, ensuring we can offer cutting-edge studies and treatments to more eligible patients.”